Varex Imaging Corp (VREX) Investment Analysis:

1. Executive Summary

Varex Imaging Corporation (NASDAQ: VREX), headquartered in Salt Lake City, Utah, represents a unique and somewhat idiosyncratic asset within the broader medical technology landscape. Originally spun off from Varian Medical Systems in 2017, Varex has established itself as the world’s largest independent supplier of medical X-ray tubes and high-performance digital detectors. The company operates as a critical "upstream" partner to the global oligopoly of medical imaging original equipment manufacturers (OEMs), providing the essential components—the "eyes" and the "engine"—that power Computed Tomography (CT), Mammography, and Fluoroscopy systems worldwide.

As of the close of Fiscal Year 2025 (FY25), Varex finds itself at a complex inflection point. The company has navigated a turbulent post-pandemic era characterized by supply chain fracturing and intense volatility in the Chinese market, yet it closed the year with a resounding fourth-quarter performance that exceeded analyst expectations on both top and bottom lines. The investment narrative is currently defined by a sharp dichotomy between its two primary reporting segments: a mature, highly cash-generative Medical business that faces low-single-digit growth headwinds, and a rapidly accelerating Industrial segment that is capitalizing on secular geopolitical insecurity and the modernization of global cargo infrastructure.

The company’s financial profile for FY25 reflects this transitional state. Varex reported full-year revenues of $845 million, a 4% increase year-over-year, driven largely by a robust 11% surge in the fourth quarter. While the company reported a GAAP net loss of $(1.70) per share—heavily distorted by a significant non-cash goodwill impairment of $93.9 million recognized in the third quarter—the underlying operational health tells a different story. Non-GAAP earnings per share (EPS) climbed 73% to $0.90, and Adjusted EBITDA grew 37% to $122 million, signaling strong operating leverage and margin expansion despite the inflationary environment.

Strategic initiatives are currently focused on three pillars: technological differentiation through the commercialization of Photon Counting CT (PC-CT) detectors, cost structure optimization via a new manufacturing footprint in India, and the diversification of revenue streams through the expansion of the Industrial cargo scanning business. The latter has shown particular promise, with the Industrial segment posting 25% year-over-year growth in Q4 FY25, validating management's pivot toward security and inspection markets.

However, the investment thesis is not without significant caveats. Varex operates with a high degree of customer concentration; its top five customers—including industry giants like Canon, GE HealthCare, and Siemens Healthineers—account for approximately 41% of total revenue. This creates a "frenemy" dynamic where Varex’s largest customers are also its potential competitors, should they choose to insource component manufacturing. Furthermore, the company’s exposure to China, which historically accounts for a significant portion of revenue and growth potential, remains a source of volatility due to oscillating tariff regimes and the rise of domestic Chinese competitors like United Imaging.

This report posits that the market is currently mispricing Varex Imaging as a stagnant, commoditized hardware supplier, effectively ignoring the embedded call option on the Industrial growth cycle and the upcoming technology refresh cycle in medical imaging. The current valuation multiples, hovering near ~6x EV/EBITDA, reflect a "no-growth" scenario that contradicts the double-digit expansion seen in the Industrial division and the margin accretion expected from the India facility ramp-up. While risks regarding execution and macroeconomics are elevated, the risk-reward profile appears asymmetrically skewed to the upside for investors willing to look past the headline GAAP noise.

2. Business Drivers & Strategic Overview

To understand Varex Imaging’s investment potential, one must dissect the "razor and razorblade" mechanics of its business model and the technological moats that protect its market share. Varex does not sell directly to hospitals or airports; it acts as the R&D and manufacturing engine for OEMs, absorbing the complexity of vacuum electronics and semiconductor fabrication so its customers can focus on system integration and software.

Medical Segment: The Foundation of Valuation

The Medical segment is the historical core of Varex, generating approximately 70-72% of total revenue ($593 million in FY25). This segment encompasses the design and manufacture of X-ray tubes, digital flat panel detectors (FPDs), high-voltage connectors, and image processing software.

Computed Tomography (CT) Tubes: The Recurring Revenue Engine

The single most critical driver for Varex is the CT tube market. Unlike general radiography tubes which may last years, CT tubes are high-performance consumables. A modern CT scanner rotates a heavy vacuum tube around a patient at high speeds (up to 200+ RPM) while generating immense heat. These tubes have a finite operational life, measured in "scan seconds" or "heat units." As hospitals utilize their CT scanners more intensively—running 24/7 to clear patient backlogs—the replacement cycle for these tubes accelerates. Varex dominates this niche because the barriers to entry are metallurgical and physical. Manufacturing a tube that can withstand 100g of G-force while dissipating 100kW of heat requires proprietary knowledge of vacuum brazing, tungsten-rhenium alloys, and liquid metal bearings. The "razorblade" aspect comes from the replacement market; once a Varex tube is designed into a CT scanner (e.g., a Canon Aquilion or a GE Revolution), regulatory approvals (FDA 510k, CE Mark) effectively lock that scanner into using Varex tubes for its entire 10-15 year lifecycle. In Q4 FY25, global sales of CT tubes were the primary driver of the Medical segment's growth, offsetting weakness in dental and other elective modalities.

The Technological Inflection: Photon Counting (PC-CT)

The strategic future of the Medical segment rests on the transition from energy-integrating detectors (EID) to Photon Counting CT (PC-CT). Traditional detectors use a scintillator to convert X-rays into light, which is then converted into an electrical signal. This two-step process introduces noise and limits resolution. Photon counting detectors, which Varex is actively commercializing, use a direct conversion material (typically Cadmium Telluride or Silicon) to measure individual X-ray photons and their specific energies. This results in:

• Higher Spatial Resolution: Ability to see tinier structures (e.g., stents, fine vessels).

• Lower Radiation Dose: Significant reduction in patient exposure.

• Spectral Information: Ability to differentiate materials (e.g., distinguishing between calcium and iodine contrast). Varex’s ability to supply merchant PC-CT detectors is crucial because while Siemens has developed its own proprietary PC technology, many other OEMs (the "rest of the world") rely on Varex to provide a competitive alternative. In FY25, Varex reported significant progress with OEM customers and research partnerships, such as with the Technical University of Munich, positioning this product line for a revenue ramp in the FY26-28 window.

Strategic Regionalization: The India Play

In response to pricing pressure in the "value" segment of the market (basic X-ray systems for emerging markets), Varex operationalized a new manufacturing facility in India in 2025. This facility is now shipping radiographic detectors, allowing Varex to compete with lower-cost Asian competitors without diluting its corporate gross margins. This move effectively bifurcates their manufacturing: high-end, complex tubes are made in the US/Europe, while high-volume, cost-sensitive detectors are moved to low-cost regions.

Industrial Segment: The Hidden Growth Star

The Industrial segment, comprising roughly 28-30% of revenue ($252 million in FY25), has transformed from a cyclical adjunct into the company’s primary growth engine, posting 10% annual growth in FY25 and an explosive 25% growth in Q4.

Security & Cargo Inspection

The driving force behind this acceleration is global insecurity. Geopolitical fragmentation, trade enforcement, and the drug trade (specifically fentanyl interdiction) have driven governments to invest heavily in Non-Intrusive Inspection (NII) infrastructure at ports and borders. Varex supplies the high-energy Linear Accelerators (Linacs) and massive detector arrays required to scan shipping containers and trucks. Crucially, Varex has moved up the value chain. Instead of just selling the "source" (the Linac), they are increasingly selling subsystems or entire scanning gantries. In FY25, the cargo business booked over $55 million in orders and shipped over 15 full systems to diverse geographies including Mexico, Iraq, Brazil, and Saudi Arabia. This shift increases the average selling price (ASP) per unit and deepens Varex’s integration into critical security infrastructure. The Total Addressable Market (TAM) for security inspection is estimated at over $1 billion, growing at a 7% CAGR, providing a long runway for this high-margin business.

Non-Destructive Testing (NDT)

Beyond security, Varex’s industrial tubes serve the NDT market, which is benefiting from the electrification of the automotive industry. Electric Vehicle (EV) batteries require rigorous X-ray inspection to detect defects that could lead to fires. As battery manufacturing capacity expands globally (and specifically in the US due to the IRA), demand for high-resolution industrial inspection systems rises. Varex reported positive trends in this vertical in Q4 FY25, alongside steady demand in food inspection and aerospace casting analysis.

Competitive Advantages (The Moat)

Varex’s competitive position is defended by a "Triple Moat":

1. Regulatory Lock-in: As noted, the regulatory burden of changing a critical component like an X-ray tube in a medical device creates immense inertia. Once Varex wins a socket, it typically keeps it for the life of the product line.

2. Manufacturing Scale & Complexity: Varex produces over 27,000 X-ray tubes and 20,000 digital detectors annually. This scale allows them to amortize the massive fixed costs of vacuum factories and clean rooms better than any smaller competitor.

3. Intellectual Property: With over 635 patents, Varex controls key innovations in anode cooling, flat panel durability, and photon counting architectures. This creates a "freedom to operate" issue for competitors trying to replicate their designs.

3. Financial Performance & Valuation

The fiscal year 2025 financial results present a complex picture that requires careful disentanglement of "headline" GAAP numbers from the underlying operational reality. The divergence between the company's reported losses and its cash generation is stark, driven by accounting adjustments rather than cash burn.

Detailed Historical Performance (FY2024–FY2025)

The following table summarizes the key financial metrics, highlighting the acceleration seen in the latter half of FY25.

Data Sources:

Deconstructing the P&L

Revenue Dynamics: The 11.2% revenue growth in Q4 FY25 is the most significant positive signal in the recent print. It indicates that the inventory destocking trends that plagued the medical device industry in 2023 and 2024 have largely abated. The Industrial segment’s 25.3% growth is particularly notable as it validates the "security supercycle" thesis. This revenue is not just volume-driven but also mix-driven, as higher-value cargo systems replace simple component sales.

Margin Expansion & Operating Leverage: Varex demonstrated impressive operating leverage in FY25. A 4% increase in revenue translated into a 37% increase in Adjusted EBITDA. This was driven by a 300 basis point expansion in Non-GAAP gross margins to 35%. Management attributes this to a favorable product mix (high-margin industrial sales), improved factory utilization, and the stabilization of freight and material costs that had spiked in prior years. The ability to hold margins above 34% despite tariff headwinds suggests strong pricing power and cost discipline.

The Goodwill Impairment (The GAAP Disconnect): The disparity between the $0.90 Non-GAAP EPS and the $(1.70) GAAP loss is primarily due to a massive $93.9 million non-cash goodwill impairment charge recorded in Q3 FY25.

• Context: Goodwill impairments typically occur when a company acknowledges that the historical value of an acquired asset is no longer justified by its future cash flows.

• Implication: While this optically hurts the "Net Income" line, it has zero impact on cash flow, liquidity, or debt covenants. It is a retrospective accounting cleanup, likely related to legacy acquisitions whose growth assumptions were reset due to higher interest rates or slower medical market growth. Investors should largely look through this charge to the Adjusted EBITDA figure, which reflects the current cash-generating capability of the business.

Balance Sheet & Liquidity Analysis

Varex's balance sheet underwent significant restructuring in FY25.

• Cash Position: The company ended the fiscal year with $155 million in cash and marketable securities, a decrease from $213 million the prior year.

• Capital Allocation: This cash reduction was deliberate. In Q3 FY25, Varex utilized approximately $75 million of cash to retire a portion of its outstanding convertible notes. This was a prudent capital allocation decision to deleverage the balance sheet and avoid potential equity dilution from conversion, given the rising rate environment.

• Debt Profile: Total debt stands at approximately $397 million to $400 million. With TTM Adjusted EBITDA of $122 million, the Net Debt / EBITDA ratio is approximately 2.0x ($397M debt - $155M cash = $242M Net Debt / $122M EBITDA). This leverage ratio is healthy and within standard covenants for an industrial technology company, providing flexibility for future R&D investment or small tuck-in acquisitions.

Valuation Multiples & Peer Comparison

As of December 2, 2025, Varex Imaging trades at a valuation that implies significant skepticism from the market.

• Current Share Price: ~$11.57.

• Market Capitalization: ~$482 Million.

• Enterprise Value (EV): ~$729 Million.

Valuation Metrics:

• P/E (Forward Non-GAAP): Trading at roughly 10x-11x projected FY26 earnings.

• EV / Adjusted EBITDA: ~6.0x.

Peer Context: When compared to its customers and peers in the MedTech space, Varex trades at a steep discount.

• GE HealthCare (GEHC): Typically trades at 12x-14x EBITDA.

• Siemens Healthineers: Trades at premium multiples due to its diverse portfolio.

• Industrial Peers (e.g., Teledyne, Amphenol): Often trade at 15x-18x EBITDA.

Analysis: Varex is being penalized for its "hardware" business model, customer concentration, and historic volatility. The market views it as a cyclical industrial supplier rather than a sticky medical technology franchise. However, if the company can sustain the growth rates seen in its Industrial segment, a re-rating towards 8x-10x EBITDA is plausible, representing significant equity upside.

4. Risk Assessment & Macroeconomic Considerations

While the valuation case is compelling, the risks facing Varex are structural and significant. The company operates in a highly interconnected global supply chain where geopolitical friction can have immediate and severe consequences.

The "China Factor": Geopolitics and Trade Policy

China is not just a market for Varex; it is a critical node in its ecosystem. Historically, China has accounted for a substantial portion of growth.

• Tariff Volatility: The company is acutely sensitive to trade wars. In Q3 FY25, Chinese customers explicitly paused shipments when tariffs spiked to ~145% levels before normalizing. Although shipments resumed, this incident highlights the fragility of the revenue stream. Management has quantified that tariffs can impact gross margins by 100-150 basis points.

• Made in China 2025 & United Imaging: The Chinese government's strategic mandate to insource high-tech medical equipment poses an existential long-term threat. United Imaging, a state-supported Chinese OEM, is aggressively gaining market share not just in China but globally. While United Imaging is currently a customer of Varex (Top 5), they are actively developing their own tube and detector capabilities. If United Imaging successfully verticalizes its supply chain, Varex could lose one of its largest growth drivers.

Customer Concentration: The "Frenemy" Dynamic

The top five customers account for ~41% of Varex's revenue. This concentration is a double-edged sword.

• Switching Costs (The Bull Case): It is incredibly difficult for Canon or GE to switch away from Varex due to regulatory filings.

• Insourcing (The Bear Case): However, these giants have the capital to insource production if they choose. GE and Siemens already manufacture some of their own high-end tubes. If they decide to expand internal capacity to capture margin, Varex would be left with only the lower-margin replacement market or smaller OEMs. This binary risk keeps the valuation multiple compressed.

Macroeconomic Headwinds

• Hospital Capex Constraints: Varex is a derivative play on hospital capital expenditure. In a high-interest-rate environment, hospitals may delay purchasing new CT scanners, opting to extend the life of existing fleets. While this boosts Varex's replacement tube business, it hurts the higher-margin detector business which relies on new system builds.

• Supply Chain Fragility: X-ray tubes require exotic materials like rhenium, specialized glass, and high-grade graphite. Sourcing disruptions, particularly from conflict zones or sanctioned entities, could halt production lines. While the company has diversified, the reliance on specialized commodities remains a vulnerability.

5. 5-Year Scenario Analysis

This scenario analysis projects the potential shareholder returns through Fiscal Year 2030 based on varying assumptions regarding market growth, technology adoption, and geopolitical stability.

Baseline Inputs (FY25 Actuals):

• Revenue: $845 Million

• Non-GAAP EPS: $0.90

• Share Price: ~$11.57

Scenario 1: Base Case (The "Muddle Through" Scenario)

• Narrative: Varex retains its leadership position but faces continued low-growth pressure in the Medical segment (~3% CAGR). The Industrial segment performs well (~6% CAGR) but does not accelerate further. The China market remains accessible but volatile, preventing significant multiple expansion. The India facility successfully ramps, stabilizing gross margins at ~35%. Photon counting sees moderate adoption in high-end systems only.

• Fundamentals:

  • Revenue CAGR (5-yr): 4.0% (Revenue reaches ~$1.03 Billion in FY30).

  • Operating Margin: Stays flat at ~9-10%.

  • Share Count: Stays flat (buybacks offset dilution).

  • FY30 EPS: ~$1.30.

  • Valuation: Market assigns a 12x P/E (historical average for low-growth component suppliers).

• Projected Price: $1.30 $\times$ 12 = $15.60

Scenario 2: High Case (The "Security & Spectral" Supercycle)

• Narrative: The Industrial segment proves to be a secular growth story, growing at 10%+ CAGR driven by global border security mandates. In Medical, Photon Counting becomes the standard of care for all mid-to-high tier CTs, driving a massive replacement cycle where Varex’s IP commands a premium. Margins expand to 12% due to operating leverage and higher ASPs.

• Fundamentals:

  • Revenue CAGR (5-yr): 7.0% (Revenue reaches ~$1.20 Billion in FY30).

  • Operating Margin: Expands to 12%.

  • FY30 EPS: ~$1.85 (Driven by revenue + margin expansion).

  • Valuation: Market re-rates the stock as a growth cyclical. 16x P/E.

• Projected Price: $1.85 $\times$ 16 = $29.60

Scenario 3: Low Case (The "Geopolitical Freeze")

• Narrative: Trade war with China escalates; tariffs make Varex uncompetitive in APAC. United Imaging fully insources its tube production. Hospital Capex freezes due to a global recession. Industrial demand slows as government budgets tighten. Revenue contracts.

• Fundamentals:

  • Revenue CAGR (5-yr): -1.0% (Revenue shrinks to ~$800 Million).

  • Operating Margin: Contracts to 6% (loss of volume leverage).

  • FY30 EPS: ~$0.55.

  • Valuation: Distressed multiple. 8x P/E.

• Projected Price: $0.55 $\times$ 8 = $4.40

Projected Share Price Trajectory (2025–2030)

Probability Weighted Outcome

$(0.25\times 29.60)+(0.50\times 15.60)+(0.25\times 4.40)=$ $16.30

Summary: ASYMMETRIC UPSIDE POTENTIAL

6. Qualitative Scorecard

This scorecard evaluates Varex Imaging across ten critical dimensions to provide a holistic view of the corporate quality beyond the financials.

Overall Blended Score: 6.5/10 Summary: UNDERVALUED MARKET LEADER

7. Conclusion & Investment Thesis

Varex Imaging Corporation presents a classic "deep value" setup within the medical technology sector. The market currently values the company as a distressed industrial manufacturer (~6x EBITDA), pricing in a permanent stagnation of its core business and discounting the significant geopolitical risks associated with its China exposure.

However, this pessimistic valuation ignores the material improvements in the company's operational profile evidenced in late FY25. The explosive 25% growth in the Industrial segment confirms that Varex is successfully pivoting toward the high-demand security/cargo market, creating a new growth engine that is less correlated with hospital capital cycles. Furthermore, the stabilization of gross margins at 35% demonstrates that the company has pricing power and can manage its supply chain costs effectively.

The catalyst path for a re-rating is clear:

1. Continued Industrial Outperformance: If Varex delivers another 2-3 quarters of double-digit growth in Industrial, analysts will be forced to re-model the revenue growth assumptions upwards.

2. Photon Counting Orders: Announcements of major OEM contract wins for PC-CT detectors would validate the R&D strategy and signal a new revenue stream for FY26-27.

3. Deleveraging: Continued pay-down of debt will transfer equity value to shareholders and reduce the risk premium.

Investment Thesis: Varex is a Buy for value-oriented investors with a time horizon of 3-5 years. The downside appears protected by the intrinsic value of the replacement tube business and the low valuation multiple, while the upside from the Industrial "supercycle" and margin expansion offers significant capital appreciation potential. The probability-weighted price target of ~$16.30 offers a compelling margin of safety.

Summary: INDUSTRIAL PIVOT PLAY

8. Technical Analysis, Price Action & Short-Term Outlook

As of early December 2025, VREX shares are displaying a constructive technical reversal pattern. The stock is trading at ~$11.57, having rebounded from a double-bottom support level near $10.00 established in mid-2025. Following the strong Q4 earnings release, the price has reclaimed its 50-day moving average ($11.73 roughly) and is challenging the resistance band of the 200-day moving average (~$10.17-$11.00 depending on the specific timeframe window used, but notably trading above the snippet-indicated 200-day average of $10.17).

The Relative Strength Index (RSI) is hovering near 51, indicating neutral momentum that is not yet overbought, leaving room for further upside. The recent volume spikes on up-days suggest institutional accumulation is returning. Short-term support is firm at $11.00, with immediate resistance at $12.50. A decisive close above $12.50 would confirm a long-term trend reversal and likely trigger a move toward the analyst average target of ~$15-$16.

Summary: BULLISH MOMENTUM BUILDING